NO20005637L - Hybridprotein for å inhibere degranulasjon av mastocyter og anvendelsen derav - Google Patents

Hybridprotein for å inhibere degranulasjon av mastocyter og anvendelsen derav

Info

Publication number
NO20005637L
NO20005637L NO20005637A NO20005637A NO20005637L NO 20005637 L NO20005637 L NO 20005637L NO 20005637 A NO20005637 A NO 20005637A NO 20005637 A NO20005637 A NO 20005637A NO 20005637 L NO20005637 L NO 20005637L
Authority
NO
Norway
Prior art keywords
inhibit
hybrid protein
mastocyte degranulation
mastocyte
degranulation
Prior art date
Application number
NO20005637A
Other languages
English (en)
Other versions
NO328361B1 (no
NO20005637D0 (no
Inventor
Hans Bigalke
Juergen Frevert
Original Assignee
Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh filed Critical Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh
Publication of NO20005637L publication Critical patent/NO20005637L/no
Publication of NO20005637D0 publication Critical patent/NO20005637D0/no
Publication of NO328361B1 publication Critical patent/NO328361B1/no

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K19/00Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/283Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against Fc-receptors, e.g. CD16, CD32, CD64
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/50Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52Constant or Fc region; Isotype
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biophysics (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Fire-Extinguishing Compositions (AREA)
NO20005637A 1998-05-13 2000-11-08 Hybridprotein og anvendelse av dette for fremstilling av et medikament for a inhibere mastcelledegranulering NO328361B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19821285 1998-05-13
PCT/EP1999/003272 WO1999058571A2 (de) 1998-05-13 1999-05-12 Hybridprotein zur hemmung der mastzelldegranulation und dessen verwendung

Publications (3)

Publication Number Publication Date
NO20005637L true NO20005637L (no) 2000-11-08
NO20005637D0 NO20005637D0 (no) 2000-11-08
NO328361B1 NO328361B1 (no) 2010-02-01

Family

ID=7867540

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20005637A NO328361B1 (no) 1998-05-13 2000-11-08 Hybridprotein og anvendelse av dette for fremstilling av et medikament for a inhibere mastcelledegranulering

Country Status (22)

Country Link
EP (1) EP1084146B1 (no)
JP (1) JP4549533B2 (no)
KR (1) KR100580541B1 (no)
CN (1) CN1241945C (no)
AT (1) ATE227739T1 (no)
AU (1) AU755513B2 (no)
BR (1) BR9910359A (no)
CA (1) CA2331274C (no)
CU (1) CU22997A3 (no)
CZ (1) CZ294376B6 (no)
DE (1) DE59903410D1 (no)
DK (1) DK1084146T3 (no)
ES (1) ES2187200T3 (no)
HK (1) HK1036994A1 (no)
HU (1) HUP0103601A3 (no)
IL (2) IL139478A0 (no)
MX (1) MXPA00011148A (no)
NO (1) NO328361B1 (no)
PL (1) PL201879B1 (no)
PT (1) PT1084146E (no)
RU (1) RU2214420C2 (no)
WO (1) WO1999058571A2 (no)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
US20040071736A1 (en) 1998-08-25 2004-04-15 Health Protection Agency Methods and compounds for the treatment of mucus hypersecretion
GB9818548D0 (en) 1998-08-25 1998-10-21 Microbiological Res Authority Treatment of mucas hypersecretion
GB9922554D0 (en) * 1999-09-23 1999-11-24 Microbiological Res Authority Inhibition of secretion from non-neuronal cells
US20080038274A1 (en) 1999-09-23 2008-02-14 Foster Keith A Inhibition of secretion from non-neuronal cells
JP2004521067A (ja) * 2000-06-28 2004-07-15 サンダース,イラ 動物(哺乳動物)における有用な用途を目的とする破傷風毒素の使用方法
GB0321344D0 (en) * 2003-09-11 2003-10-15 Health Prot Agency Re-targeted toxin conjugates
GB0426394D0 (en) 2004-12-01 2005-01-05 Health Prot Agency Fusion proteins
KR100845278B1 (ko) * 2006-08-04 2008-07-09 포항공과대학교 산학협력단 비만 세포의 활성을 유도하는 펩타이드 및 이를 포함하는면역조절제
EP2310029B1 (en) 2008-06-12 2019-04-03 Ipsen Bioinnovation Limited Fusion proteins for use in the treatment of cancer
CN102112145B (zh) 2008-06-12 2014-07-30 辛它可辛有限公司 神经内分泌病的抑制
AU2009275846B2 (en) * 2008-07-31 2014-09-25 L'institut National Des Sciences Appliquees (Insa) Constructs and methods for the production and secretion of polypeptides
GB0820970D0 (en) 2008-11-17 2008-12-24 Syntaxin Ltd Suppression of cancer
CN102241774B (zh) * 2010-05-27 2014-05-14 四川大学 重组IgE-Fc-抗EGFR单链抗体融合蛋白及其制备方法和用途
GB201108108D0 (en) 2011-05-16 2011-06-29 Syntaxin Ltd Therapeutic fusion proteins
US20140056870A1 (en) 2012-08-27 2014-02-27 Allergan, Inc. Fusion proteins
GB201312317D0 (en) 2013-07-09 2013-08-21 Syntaxin Ltd Cationic neurotoxins
US10647750B2 (en) 2015-01-09 2020-05-12 Ipsen Bioinnovation Limited Cationic neurotoxins
GB201517450D0 (en) 2015-10-02 2015-11-18 Ipsen Biopharm Ltd Method
EP3263710A1 (en) 2016-07-01 2018-01-03 Ipsen Biopharm Limited Production of activated clostridial neurotoxins
GB201815817D0 (en) 2018-09-28 2018-11-14 Ispen Biopharm Ltd Clostridial neurotoxins comprising and exogenous activation loop
GB201900621D0 (en) 2019-01-16 2019-03-06 Ipsen Biopharm Ltd Labelled polypeptides
GB201914034D0 (en) 2019-09-30 2019-11-13 Ipsen Biopharm Ltd Treatment of neurological disorders
GB202100566D0 (en) 2021-01-15 2021-03-03 Ipsen Biopharm Ltd Treatment of brain damage
GB202104294D0 (en) 2021-03-26 2021-05-12 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an exogenous activation loop
WO2022208091A1 (en) 2021-03-30 2022-10-06 Ipsen Biopharm Limited Treatment of pain & inflammatory disorders
CN117396217A (zh) 2021-03-30 2024-01-12 益普生生物制药有限公司 无催化活性的梭菌神经毒素用于疼痛和炎性疾病的治疗
GB202116795D0 (en) 2021-11-22 2022-01-05 Ipsen Biopharm Ltd Treatment of visceral pain
PL244930B1 (pl) 2021-12-08 2024-04-02 Gdanski Univ Medyczny Zastosowanie 2-metoksyestradiolu w leczeniu mastocytozy
GB202214232D0 (en) 2022-09-28 2022-11-09 Ispen Biopharm Ltd Clostridial neurotoxins comprising an activating exogenous protease cleavage site
GB202214229D0 (en) 2022-09-28 2022-11-09 Ipsen Biopharm Ltd Clostridial neurotoxins comprising an activating endosomal protease cleavage site

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9305735D0 (en) * 1993-03-19 1993-05-05 North John R Novel agent for controlling cell activity
IL116436A (en) * 1995-12-18 2006-12-31 Yissum Res Dev Co Fc?Á-PE CHIMERIC PROTEIN FOR TARGETED TREATMENT OF ALLERGY RESPONSES AND

Also Published As

Publication number Publication date
KR20010042825A (ko) 2001-05-25
HUP0103601A3 (en) 2004-06-28
JP2002514659A (ja) 2002-05-21
WO1999058571A2 (de) 1999-11-18
CZ294376B6 (cs) 2004-12-15
CZ20004161A3 (cs) 2001-04-11
PL201879B1 (pl) 2009-05-29
KR100580541B1 (ko) 2006-05-16
BR9910359A (pt) 2001-01-09
NO328361B1 (no) 2010-02-01
IL139478A (en) 2008-06-05
DK1084146T3 (da) 2003-02-03
DE59903410D1 (de) 2002-12-19
NO20005637D0 (no) 2000-11-08
MXPA00011148A (es) 2003-04-22
EP1084146A2 (de) 2001-03-21
CN1241945C (zh) 2006-02-15
AU755513B2 (en) 2002-12-12
CU22997A3 (es) 2004-10-12
RU2214420C2 (ru) 2003-10-20
CA2331274A1 (en) 1999-11-18
CN1300295A (zh) 2001-06-20
JP4549533B2 (ja) 2010-09-22
WO1999058571A3 (de) 2000-02-03
AU4260599A (en) 1999-11-29
HUP0103601A2 (hu) 2002-01-28
PT1084146E (pt) 2003-02-28
HK1036994A1 (en) 2002-01-25
ES2187200T3 (es) 2003-05-16
IL139478A0 (en) 2001-11-25
EP1084146B1 (de) 2002-11-13
ATE227739T1 (de) 2002-11-15
CA2331274C (en) 2010-04-06
PL344752A1 (en) 2001-11-19

Similar Documents

Publication Publication Date Title
NO20005637D0 (no) Hybridprotein for å inhibere degranulasjon av mastocyter og anvendelsen derav
BR9407377A (pt) Toxina hibrida
DE69907439D1 (de) Reinigung von proteinen durch ionenaustauschchromatographie
ATE317441T1 (de) Cathepsin-02-protease
EP1905830B8 (en) Cell-permeable peptide inhibitors of the JNK signal transduction pathway
ATE304592T1 (de) Automatisierung im proteinentwurf durch proteinbibliotheken
ME00185B (me) Specifični agensi koji vezuju humani angiopoetin-2
MXPA03010762A (es) Peptidos enlazantes de iap y ensayos para identificar los compuestos que enlazan el iap.
DE60019458D1 (de) Stabilisierendes verdünnungsmittel für polypeptide und antigene
TW200510528A (en) Polypeptide inducing apoptosis
UY28641A1 (es) Anticuerpos
EP1970070A3 (en) Cell-permeable peptide inhibitors of the JNK signal transduction pathway
CY1110381T1 (el) Πεπτιδια χ-κωνοτοξινης ως αναστολεις των νευρωνικων αμινικων μεταφορεων
FR2816410B1 (fr) Necessaire de detection de la proteine esm-1 et procede de detection mettant en oeuvre ledit necessaire
NO20055210D0 (no) Inhibitorproteiner av en protease og anvendelse derav
ATE450544T1 (de) Streptavidin-bindungspeptid
IL145689A0 (en) Methods
PT723552E (pt) Oligopeptidos derivados de fragmentos de proteina reactiva c
ATE228847T1 (de) Inhibitoren von katalytischen antikörpern
CY1109904T1 (el) Προαγωγεας της il-18bp, η παρασκευη και χρηση του
WO2003087145A3 (en) Purified polypeptides involved in quorum sensing
ATE433953T1 (de) Peptiddeformylaseinhibitoren
AU2003280359A1 (en) Phosphoamidase assay
TNSN99075A1 (fr) Sequence signal synthetique pour la secretion des proteines chez les streptomyces et les actinomycetes.

Legal Events

Date Code Title Description
MM1K Lapsed by not paying the annual fees